PSTX241220P2500
- 0.01
- 0.000.00%
Poseida Therapeutics Newsroom
Piper Sandler Maintains Poseida Therapeutics(PSTX.US) With Hold Rating, Maintains Target Price $10
Piper Sandler Downgrades Poseida Therapeutics(PSTX.US) to Hold Rating, Maintains Target Price $10
Roche's Acquisition Offer Leads to Hold Rating for Poseida Therapeutics Amid Promising Pipeline and Financial Uncertainties
The Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis
Key Deals This Week: EnLink Midstream, Peabody, StoneCo, UniCredit and More
10 Health Care Stocks With Whale Alerts In Today's Session
Catalyst Watch: November Jobs, OPEC+ Meeting, Marvell, Salesforce Earnings
Should You Buy Poseida Therapeutics, Inc. (PSTX) After Golden Cross?
Insider Sale: Executive Chairman of $PSTX (PSTX) Sells 30,000 Shares
Wall Street Analysts Think Poseida Therapeutics (PSTX) Could Surge 49.25%: Read This Before Placing a Bet
A Quick Look at Today's Ratings for Poseida Therapeutics(PSTX.US), With a Forecast Between $9 to $9
Poseida Therapeutics Downgraded to Neutral From Overweight at Cantor Fitzgerald
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Poseida Therapeutics Cut to Market Perform From Outperform by William Blair
Why This Gene-Therapy Company's Stock Is Rising 228% -- Barrons.com
Poseida Therapeutics Up Nearly 225%, On Pace For Record High Close -- Data Talk
US Stocks Mixed; Best Buy Posts Downbeat Earnings
Shareholder Alert: Ademi LLP Investigates Whether Poseida Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Sector Update: Health Care Stocks Mixed Premarket Tuesday
Poseida Therapeutics Analyst Ratings